These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. 3D optical/CT as a preclinical companion imaging platform for glioblastoma drug development. Molotkov A; Doubrovin M; Bhatt N; Hsu FC; Beserra A; Chopra R; Mintz A Drug Deliv; 2020 Dec; 27(1):1686-1694. PubMed ID: 33263448 [TBL] [Abstract][Full Text] [Related]
7. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523 [TBL] [Abstract][Full Text] [Related]
8. [Clinical application of positron emission tomography and 18FDG to brain tumor]. Momose T Nihon Rinsho; 2005 Sep; 63 Suppl 9():242-9. PubMed ID: 16201530 [No Abstract] [Full Text] [Related]
10. Molecular imaging of T cell co-regulator factor B7-H3 with Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047 [TBL] [Abstract][Full Text] [Related]
11. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187 [TBL] [Abstract][Full Text] [Related]
12. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164 [TBL] [Abstract][Full Text] [Related]
13. Brain: positron emission tomography tracers beyond [¹⁸F]fluorodeoxyglucose. Singhal T; Alavi A; Kim CK PET Clin; 2014 Jul; 9(3):267-76. PubMed ID: 25030390 [TBL] [Abstract][Full Text] [Related]
14. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma]. Adam J; Tomasic G; Robert C Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041 [TBL] [Abstract][Full Text] [Related]
15. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495 [TBL] [Abstract][Full Text] [Related]
16. A decade of immune-checkpoint inhibitors in cancer therapy. Robert C Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879 [TBL] [Abstract][Full Text] [Related]
17. F-18 flurodeoxyglucose negative, F-18 fluoride accumulating in a brain metastasis in a treated case of carcinoma of the breast. Tripathi M; Jaimini A; Singh N; Jain N; D'Souza M; Kaur P; Singh D; Sharma R; Mondal A Clin Nucl Med; 2009 May; 34(5):287-9. PubMed ID: 19387204 [No Abstract] [Full Text] [Related]
18. Evaluation of treatment response using integrated 18F-labeled choline positron emission tomography/magnetic resonance imaging in adolescents with intracranial non-germinomatous germ cell tumours. Tsouana E; Stoneham S; Fersht N; Kitchen N; Gaze M; Bomanji J; Fraioli F; Hargrave D; Shankar A Pediatr Blood Cancer; 2015 Sep; 62(9):1661-3. PubMed ID: 25854508 [TBL] [Abstract][Full Text] [Related]
19. Programmed death ligand 1 expression and CD8 Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752 [TBL] [Abstract][Full Text] [Related]
20. (18)F FDOPA uptake in brain metastasis of breast cancer. Chiaravalloti A; Floris R; Schillaci O Rev Esp Med Nucl Imagen Mol; 2016; 35(1):46-7. PubMed ID: 26117270 [No Abstract] [Full Text] [Related] [Next] [New Search]